MedTrace Logo

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

NCT04871542 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2062

Last updated 2026-05-05

No results posted yet for this study

Summary

This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.

Conditions

  • Malignant Solid Neoplasm

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood sample

OTHER

Questionnaire Administration

Complete questionnaires

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Krishna S Gunturu · SWOG Cancer Research Network

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2026-09-30
Completion
2028-03-14

Countries

  • United States
  • Chile
  • Guam
  • Mexico
  • Uruguay

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871542 on ClinicalTrials.gov